Clinical Trial Update: Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating the safety and immunogenicity of the Ebola vaccine Ervebo (rVSVΔG-ZEBOV-GP) when dosed concurrently with booster dose…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Ervebo (rVSVΔG-ZEBOV-GP)
• mRNA COVID-19 vaccine booster

Snippet

Sponsor: University of Birmingham | Conditions: Ebola Virus Disease, COVID-19 | Phase 4 | Status: NOT_YET_RECRUITING